Tepezza (teprotumumab-trbw) / Roche, Amgen 
Welcome,         Profile    Billing    Logout  
 18 Diseases   3 Trials   3 Trials   723 News 


«123456789»
  • ||||||||||  Tepezza (teprotumumab) / Horizon Therapeutics, Genmab
    Review, Journal:  Teprotumumab: First Approval. (Pubmed Central) -  Dec 17, 2020   
    Based on positive results from two multinational clinical trials teprotumumab was recently approved for this indication in the US. This article summarizes the milestones in the development of teprotumumab leading to this first approval for thyroid eye disease.
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Trial termination, Combination therapy, Metastases:  A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer (clinicaltrials.gov) -  Nov 13, 2020   
    P2,  N=6, Terminated, 
    This article summarizes the milestones in the development of teprotumumab leading to this first approval for thyroid eye disease. Completed --> Terminated; Due to the discontinuation of compound development, this study has been terminated.
  • ||||||||||  Tepezza (teprotumumab) / Horizon Therapeutics, Genmab
    Journal:  Teprotumumab for thyroid-associated ophthalmopathy : OPTIC (Pubmed Central) -  Nov 12, 2020   
    Completed --> Terminated; Due to the discontinuation of compound development, this study has been terminated. No abstract available
  • ||||||||||  Tepezza (teprotumumab) / Horizon Therapeutics, Genmab
    [VIRTUAL] PO305: Improvement in the Fellow Eye of Patients With TED: Pooled Analyses From the Teprotumumab Studies () -  Nov 11, 2020 - Abstract #AAO2020AAO_434;    
    Mean (±SE) fellow-eye proptosis change was −2.39 ± 0.16 mm with teprotumumab versus +0.15 ± 0.16 mm with placebo (P < .001), and mean (±SE) CAS change was −3.42 ± 0.17 with teprotumumab versus −2.00 ± 0.16 with placebo (P < .001). Conclusion The findings support the bilateral effect of teprotumumab and its efficacy in less severe TED.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Retrospective data, Journal:  Treatment strategies for Graves' ophthalmopathy: a network meta-analysis. (Pubmed Central) -  Nov 2, 2020   
    A robust recommendation regarding the best treatment cannot be made, because most evidence was rated as low or very low quality according to the Grading of Recommendations, Assessment, Development and Evaluations framework. Large RCTs and individual participant data meta-analyses are necessary to confirm these results and explore potential moderators.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Enbrel (etanercept) / Pfizer, Amgen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Review, Journal:  Novel therapies for thyroid autoimmune diseases: An update. (Pubmed Central) -  Oct 27, 2020   
    Teprotumumab (a human monoclonal anti-IGF-1R blocking antibody) has been investigated in a trial, showing it was very effective in GO patients. Still, more studies are needed for new therapies targeting autoimmune thyroid disorders.
  • ||||||||||  Tepezza (teprotumumab) / Horizon Therapeutics, Genmab
    [VIRTUAL] SD-07: Thyroid Eye Disease: Clinical Assesment, Mangement, and New Treatment (Track 2 - Academy at Home) -  Oct 14, 2020 - Abstract #AAOPT2020AAOPT_955;    
    A new therapy has been approved by the FDA, teprotumumab a insulin like growth factor receptor agonist...Emerging treatment pathways based on this new therapy will be discussed. Clinical cases to demonstrate the principles of clinical diagnosis, assessment, and treatment will be presented.
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    New P4 trial:  A Study Evaluating TEPEZZA (clinicaltrials.gov) -  Oct 11, 2020   
    P4,  N=39, Not yet recruiting, 
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Enrollment open:  A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) (clinicaltrials.gov) -  Sep 14, 2020   
    P1,  N=25, Recruiting, 
    Clinical cases to demonstrate the principles of clinical diagnosis, assessment, and treatment will be presented. Not yet recruiting --> Recruiting
  • ||||||||||  Tepezza (teprotumumab) / Horizon Therapeutics, Genmab
    Journal:  Teprotumumab: a disease modifying treatment for graves' orbitopathy. (Pubmed Central) -  Jul 9, 2020   
    It may herald a new era in the treatment of thyroid eye disease and could offer an alternative to surgery and its associated complications. Additional studies will continue to shape the treatment of GO and define the role of teprotumumab within the treatment paradigm.
  • ||||||||||  Tepezza (teprotumumab) / Horizon Therapeutics, Genmab
    [VIRTUAL] Genome-Wide Association Study of Short-Acting Bronchodilator Response Identifies Novel Pharmacogenetic Loci in SPIROMICS (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_2283;    
    We identified a novel locus in GLB1 , a lysosomal pathway gene differentially expressed in pediatric allergic asthma (Lu Mol Med Rep 2015). We also identified SNPs adjacent to DSP , a risk locus for idiopathic pulmonary fibrosis and interstitial lung abnormalities (Hobbs Am J Resp Crit Care Med 2019), and in RBMS3 , a gene associated with lymphocyte glucocorticoid sensitivity (Maranville Am J Hum Genet 2013).
  • ||||||||||  Tepezza (teprotumumab) / Horizon Therapeutics, Genmab
    Journal:  Teprotumumab for Active Thyroid Eye Disease. (Pubmed Central) -  May 23, 2020   
    There was no meaningful exposure-response relationship at the selected TED dose regimen for both efficacy and safety endpoints, supporting the teprotumumab dose regimen used in TED patients. No abstract available
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    [VIRTUAL] AWARENESS OF THYROID EYE DISEASE, AN AUTOIMMUNE CONDITION, AMONG RHEUMATOLOGISTS () -  May 22, 2020 - Abstract #EULAR2020EULAR_2941;    
    Nearly all surveyed rheumatologists were aware of the signs and symptoms of TED, although most did not actively manage or administer medication for TED. Given the high level of interest in infusing novel, TED-specific biologics, rheumatologists may become an integral part of TED patient management with the approval of a new biologic, teprotumumab, for thyroid eye disease.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    [VIRTUAL] Moderate to Severe Active Thyroid Eye Disease () -  May 15, 2020 - Abstract #ENDOI2020ENDO-I_76;    
    Teprotumumab was recently approved by the FDA for treatment of TED. As new treatment options emerge, the treatment paradigm for TED will continue to evolve.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Journal:  Immunotherapies for thyroid eye disease. (Pubmed Central) -  May 7, 2020   
    As new treatment options emerge, the treatment paradigm for TED will continue to evolve. This short review summarizes the recent research developments in this area.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Review, Journal:  New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. (Pubmed Central) -  Apr 17, 2020   
    In addition, targeted biologic therapies have shown promise, including teprotumumab, which reduces proptosis, rituximab (anti-CD20), which reduces inflammation, and tocilizumab, which potentially benefits both of these parameters...The pathophysiology of Graves orbitopathy has also been revised with identification of new potential therapeutic targets. In this Review we provide an up-to-date overview of the field, outline the optimal management of Graves orbitopathy and summarize the research developments in this area to highlight future research questions and direct future clinical trials.
  • ||||||||||  Tepezza (teprotumumab) / Horizon Therapeutics, Genmab
    Journal:  A New Era in the Treatment of Thyroid Eye Disease. (Pubmed Central) -  Mar 29, 2020   
    Therefore, proptosis as well as strabismus and its resulting diplopia often remain, impacting patient well-being and quality of life over the long-term. Targeted molecular therapy using teprotumumab demonstrates disease-modifying benefits with the potential to shift the paradigm for TED treatment.
  • ||||||||||  Tepezza (teprotumumab) / Horizon Therapeutics, Genmab
    Genome-Wide Association Study of Short-Acting Bronchodilator Response Identifies Novel Pharmacogenetic Loci in SPIROMICS (PHILADELPHIA MARRIOTT DOWNTOWN, Grand Ballroom Salon B-D (Level 5)) -  Mar 15, 2020 - Abstract #ATS2020ATS_4809;    
    We identified a novel locus in GLB1, a lysosomal pathway gene differentially expressed in pediatric allergic asthma (Lu Mol Med Rep 2015). We also identified SNPs adjacent to DSP, a risk locus for idiopathic pulmonary fibrosis and interstitial lung abnormalities (Hobbs Am J Resp Crit Care Med 2019), and in RBMS3, a gene associated with lymphocyte glucocorticoid sensitivity (Maranville Am J Hum Genet 2013).
  • ||||||||||  Tepezza (teprotumumab) / Horizon Therapeutics, Genmab
    Journal:  Teprotumumab for the Treatment of Active Thyroid Eye Disease. (Pubmed Central) -  Feb 14, 2020   
    P3
    Among patients with active thyroid eye disease, teprotumumab resulted in better outcomes with respect to proptosis, Clinical Activity Score, diplopia, and quality of life than placebo; serious adverse events were uncommon. (Funded by Horizon Therapeutics; OPTIC ClinicalTrials.gov number, NCT03298867, and EudraCT number, 2017-002763-18.).
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Faculty (Room 202) -  Dec 14, 2019 - Abstract #ENDO2020ENDO_758;    
    Teprotumumab is expected to be FDA approved for treatment of moderate to severe active TED in early 2020. As new treatment options emerge, the treatment paradigm for TED will continue to evolve.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Faculty (Room 202) -  Dec 14, 2019 - Abstract #ENDO2020ENDO_757;    
    Teprotumumab was recently approved by the FDA for treatment of TED. As new treatment options emerge, the treatment paradigm for TED will continue to evolve.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Faculty (Room 3) -  Dec 14, 2019 - Abstract #ENDO2020ENDO_601;    
    Teprotumumab is expected to be FDA approved for treatment of moderate to severe active TED in early 2020. As new treatment options emerge, the treatment paradigm for TED will continue to evolve.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
    Faculty (Room 3) -  Dec 14, 2019 - Abstract #ENDO2020ENDO_600;    
    Teprotumumab was recently approved by the FDA for treatment of TED. As new treatment options emerge, the treatment paradigm for TED will continue to evolve.